Related Experiment Video
Updated: May 20, 2026
07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Glycopeptide-based antibody detection in multiple sclerosis by surface plasmon resonance
Feliciana Real-Fernández1, Irene Passalacqua, Elisa Peroni
1Laboratory of Peptide & Protein Chemistry & Biology, Polo Scientifico e Tecnologico, University of Florence; I-50019 Sesto Fiorentino (FI), Italy. real@toscanabiomarkers.com
Sensors (Basel, Switzerland)
|July 11, 2012
Summary
A new glycopeptide-based biosensor shows promise for detecting multiple sclerosis (MS) specific antibodies in patient sera. This surface plasmon resonance technology offers a simpler, non-invasive diagnostic tool for MS.
Area of Science:
- Biomedical Engineering
- Immunology
- Neurology
Background:
- Magnetic resonance imaging (MRI) is the current gold standard for multiple sclerosis (MS) diagnosis and prognosis.
- Simpler, non-invasive diagnostic assays for MS are needed to complement existing methods like cerebrospinal fluid analysis.
- Current diagnostic methods for MS lack sufficient simplicity and non-invasiveness for routine clinical use.
Purpose of the Study:
- To evaluate the feasibility of a novel glycopeptide-based biosensor for detecting MS-specific antibodies in human sera.
- To assess the potential of surface plasmon resonance (SPR) technology for real-time autoantibody detection in MS diagnosis.
- To develop a simpler, non-invasive diagnostic technique for clinical application in multiple sclerosis.
Main Methods:
- Immobilization of the glycopeptide antigen CSF114(Glc) onto a gold sensor chip for surface plasmon resonance (SPR) analysis.
- Optimization of the SPR method for direct, real-time detection of autoantibodies in patient sera.
- Screening of sera from 61 multiple sclerosis patients and 60 healthy blood donors using the developed biosensor and a validated ELISA.
Main Results:
- The glycopeptide-based biosensor successfully detected MS-specific antibodies directly in sera using SPR technology.
- Receiver operating characteristic (ROC) analysis determined an optimal diagnostic cut-off, yielding a sensitivity of 36% and a specificity of 95%.
- Results from the biosensor assay were compared with those obtained from a previously validated enzyme-linked immunosorbent assay (ELISA).
Conclusions:
- The developed glycopeptide-based biosensor demonstrates high specificity (95%) for detecting multiple sclerosis (MS) associated autoantibodies in patient sera.
- While sensitivity requires improvement, the biosensor presents a feasible, non-invasive alternative for MS diagnosis, particularly for routine clinical application.
- Surface plasmon resonance (SPR) technology combined with glycopeptide antigens offers a promising platform for developing simpler MS diagnostic tools.
